Form 4: Glaukos Corp Director Aimee S. Weisner Executes Stock Option and Sells Shares

Director Aimee S. Weisner exercised stock options and sold 25,000 shares of Glaukos Corp stock on August 8, 2024.

Summary

• On August 8, 2024, Aimee S. Weisner, a director of Glaukos Corporation, exercised stock options to acquire 25,000 shares of common stock at a price of $32 per share.
• Simultaneously, Weisner sold 25,000 shares of Glaukos Corp common stock at a price of $120 per share.
• Following these transactions, Weisner directly owns 30,119 shares of Glaukos Corp common stock.
• Weisner also indirectly owns 15,000 shares through the Saeman-Weisner Family Trust and 2,000 shares through the Weisner Saeman Family Irrevocable Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects routine insider trading activity. The sale could be perceived slightly negatively, but the option exercise suggests confidence.

Positives

• The exercise of stock options demonstrates the director's confidence in the company.
• The sale of shares at $120 provides a significant profit for the director.

Negatives

• The sale of 25,000 shares could be interpreted negatively by the market, although it is a relatively small percentage of the total outstanding shares.

Risks

• There are no specific risks mentioned in this document, but insider selling can sometimes create negative market sentiment.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical and medical device industry, as it can provide insights into management's perspective on the company's future performance. This activity is a normal part of executive compensation.

Comparison to Industry Standards

• Insider trading is a common practice among executives in publicly traded companies, particularly in the pharmaceutical and medical device sectors.
• Executives often exercise stock options and sell shares to diversify their holdings or for personal financial planning.
• The timing and volume of these transactions are closely scrutinized by investors and regulators to ensure compliance with insider trading laws.

Stakeholder Impact

• Shareholders may react to the insider selling, but the overall impact is likely to be minimal given the relatively small volume of shares sold.

Key Dates